Brussels - UNIV UZ Brussel

Brussels 1090

0 studies enrolling now · 11 studies all time

What they study most

Atrial Fibrillation, Bronchiectasis, Cystic Fibrosis, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Heart Failure, Hemorrhage, Idiopathic Pulmonary Fibrosis, Kidney Disease, Chronic, Percutaneous Coronary Intervention, Secondary Prevention, Venous Thromboembolism

Studies at this site

• A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) — Completed
• A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease — Completed
• A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure — Completed
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis — Completed
• A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1 — Stopped early
• Safety of Dabigatran Etexilate in Blood Clot Prevention in Children — Completed
• This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses) — Completed
• Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) — Completed
• Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) — Completed
• Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) — Completed
• Reversal of Dabigatran Anticoagulant Effect With Idarucizumab — Completed